
BLSM Stock Forecast & Price Target
BLSM Analyst Ratings
Bulls say
BlossomHill Therapeutics is attractive because its lead BH-30643 is already showing differentiated clinical activity in a large, clinically validated EGFR-mutant NSCLC market, with 53% partial responses in 34 evaluable C797S+ patients and 78% ORR in 27 TKI-naive classical EGFR+ patients, while remaining well-tolerated and CNS-active. The company’s pipeline is further de-risked by BH-30236, which has shown early anti-leukemic activity in R/R AML and HR-MDS, including 28.6% with ≥50% marrow blast reductions, a 36% ORR in 11 evaluable R/R AML patients, and manageable dosing, supporting a second credible franchise in a high-unmet-need setting. Financially, BlossomHill ended 2Q26 with about $95 million in cash and equivalents and added $168.3 million from its August 2026 IPO, implying runway into 2Q28 and giving it time to reach key readouts in 1Q27 and 2027.
Bears say
BlossomHill Therapeutics is a pre-profit clinical-stage biotech with no assurance it will ever generate earnings, and the need to raise additional capital remains a material risk if development costs continue to rise. Its lead asset BH-30643 also appears to face a difficult competitive and regulatory path, with safety concerns centered on hepatotoxicity, including treatment-related Grade ≥3 ALT elevations in 7.1% of patients and Grade 3 AST elevations in 4.6%, which may limit differentiation versus established EGFR therapies. Beyond BH-30643, the broader pipeline is still unproven, as the company’s second clinical program and preclinical KRAS asset have not yet established proof of concept, leaving fundamental value highly dependent on uncertain clinical data.
This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BLSM Analyst Forecast & Price Prediction
Start investing in BLSM
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Blossomhill Therapeutics Inc (BLSM) Forecast
BLSM Analyst Forecast & Price Prediction
Start investing in BLSM
Order type
Buy in
Order amount
Est. shares
0 shares